MADISON, Wis.  – Sep 20, 2022 –  Invenra Inc., a company developing next generation therapeutic antibodies, announced today that Chief Scientific Officer Daniel Pereira, Ph.D., will present preclinical data supporting the ongoing development of INV322, an antibody-based cancer therapeutic. The preclinical research findings will be presented at the 13th Annual World Bispecific Summit, Thursday, September 22nd, 2022 and at the Immuno-Oncology Summit, Wednesday, October 12th, 2022, both in Boston.

The presentation will highlight preclinical data related to the lead candidate INV322, a SNIPER™ Bispecific Antibody co-targeting CTLA-4 and CD25. In vitro studies have characterized avidity-mediated binding of INV322 to these tumor Treg antigens as well as an antibody dependent cell cytotoxicity (ADCC) mediated mode of action. In vivo studies using a murine surrogate also show potent anti-tumor responses after a single dose and selective regulatory T cell (Treg) depletion in syngeneic mice. Moreover, synergistic anti-tumor activity was also observed in combinations with anti-PD-1 and anti-PD-L1 agents.

“We are very pleased with the strong preclinical data that our research team has generated with INV322 using our proprietary multispecific B-Body® Platform. INV322 also appears well tolerated in ongoing toxicology studies and thus we are also encouraged by its therapeutic potential as we progress our IND-enabling activities,” said Pereira. “These efforts are also providing validation for both the SNIPER Bispecific antibody therapeutics approach, and our robust multispecific B-Body Platform.”

Jonathan Davis, Ph.D., Invenra VP of Innovation and Strategy, will also be presenting on the Invenra B-Body Platform at the 13th Annual World Bispecific Summit. “Our platform has binding, biophysical, and manufacturing properties equivalent to the best conventional monoclonal antibodies, and far superior to the typical bispecific antibody platform,” said Davis. “We are very excited to see the B-Body Platform and SNIPER Bispecific antibodies advancing in multiple indications and believe this will be a pivotal platform for bispecific antibody therapeutics.”

About INV322

INV322 is a next generation anti-CTLA-4 x CD25 bispecific mAb developed using Invenra’s high-developability B-Body Platform. Using the SNIPER Bispecific approach, the antibody was designed with optimized affinities for both antigens, permitting avid antibody binding specifically when both antigens are present. The antibody was also optimized for an ADCC-mediated MOA and has exhibited excellent developability properties at scale.

About Invenra Inc.

With a vision to cure cancer and other immune-related diseases, Invenra is redefining what is possible by harnessing the human immune response and creatively optimizing therapies to eradicate even the most challenging of therapeutic targets. Since our founding, we have developed an extensive and proprietary set of biological tools that have enabled us to design and develop bi- and multi-specific antibody candidates with novel mechanisms of action that have demonstrated best-in-class activity in preclinical studies to date. The foundation of our innovation is our B-Body® Platform, which enables versatile antibody constructs designed for improved expression, purification, stability, and binding of a wide variety of potential cargo to our human IgG-like scaffolds. Building off this foundation, we have developed a fully integrated candidate discovery platform that has already delivered multiple preclinical candidates for us and our partners. For more information, please visit

Link to the original press release